{"type":"trials","record":{"id":39108,"source_id":"clinicaltrials-gov","external_id":"NCT03958630","title":"PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand","brief_summary":"Background: Aging-related progressive neurological disorders include frontotemporal dementia, Lou Gehrig s disease, and Alzheimer s disease. Little is known about what causes these disorders. Brain inflammation may be involved. Researchers want to see if scans using radioactive drugs can show brain inflammation. Objective: To see if the drug \\[11C\\]ER176 can show inflammation in the brain in people with certain progressive neurological disorders compared to healthy adults. Also to find genes that might be associated with or cause these disorders. Eligibility: People ages 18 and older with an aging-related neurological disorder, and healthy adults Design: Participants will be screened with a medical history, physical exam, neurological exam, psychiatric history, and blood tests. Participants will have 2-5 visits for the first session. They will have 2 PET scans and 1 MRI scan. They may have 3 more sessions: 6 months to about 18 months later, 1 year after that, and about 30 months to 5 years after the first visit. There may be up to 20 total visits. For the scans, participants will lie on a bed that slides into the scanners. For the PET scans, a strap will fix their head in place. A radioactive drug will be injected through a catheter. A needle will guide a thin plastic tube into an arm vein. Additional catheters may be put in place to draw blood. Each PET will take 2 hours. The MRI will take 30 60 minutes. At each session, participants will have a brief interview, medical history, physical exam, blood and urine tests, heart tests, and memory and thinking tests. They may donate blood for DNA tests.","overall_status":"Terminated","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"National Institute of Mental Health (NIMH)","enrollment":13,"countries":["United States"],"start_date":"2019-07-03","completion_date":"2023-12-04","last_update_date":"2024-05-01","source_url":"https://clinicaltrials.gov/study/NCT03958630","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:14.411411+00:00","last_seen_at":"2026-09-25T06:20:07.141+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"18 Years","comparator":null,"organization":"National Institutes of Health Clinical Center (CC)","interventions":["11C-ER176","11C-PIB","Positron Emission Tomography (PET) Scan"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Standard Uptake Value Ratio Compared to the Cerebellum (SUVR) Area Under the Curve (AUC) (60-90min) — Up to 90 minutes…"],"design_description":"NON RANDOMIZED · PARALLEL · DIAGNOSTIC · NONE","source_has_results":true},"controlled_terms":["Dementia","11C-ER176","11C-PIB","Positron Emission Tomography (PET) Scan"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: neuroinflammation.","quality_checked_at":"2026-09-25T06:20:08.679024+00:00","duplicate_cluster_key":"id:nct03958630","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-07-03 to 2023-12-04","comparator":null,"confidence":"structured-source","population":"ALL · 18 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:07.162Z","intervention":["11C-ER176","11C-PIB","Positron Emission Tomography (PET) Scan"],"participants":13,"study_design":"NON RANDOMIZED · PARALLEL · DIAGNOSTIC · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Standard Uptake Value Ratio Compared to the Cerebellum (SUVR) Area Under the Curve (AUC) (60-90min) — Up to 90 minutes…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"neuroinflammation","is_published":true,"match_reasons":["Title contains controlled term: neuroinflammation.","Title supplies longevity context: aging.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Neuroinflammation","slug":"neuroinflammation"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/39108","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}